Anna D. Garrett, PharmD, BCPS, CPP

Articles by Anna D. Garrett, PharmD, BCPS, CPP

coagulation counseling

ByAnna D. Garrett, PharmD, BCPS, CPP

January 1st 2008

coagulation counseling

ByAnna D. Garrett, PharmD, BCPS, CPP

November 1st 2007

FOLIC ACID REDUCES RISK OF STROKE

ByAnna D. Garrett, PharmD, BCPS, CPP

October 1st 2007

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

FDA APPROVES UPDATED WARFARIN INFO

ByAnna D. Garrett, PharmD, BCPS, CPP

October 1st 2007

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

FONDAPARINUX MAY BE OPTION FOR HIT

ByAnna D. Garrett, PharmD, BCPS, CPP

October 1st 2007

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

INTERACTION REGISTRY AVAILABLE

ByAnna D. Garrett, PharmD, BCPS, CPP

October 1st 2007

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

META-ANALYSIS REINFORCES VALUE OF WARFARIN AND ANTIPLATELET AGENTS

ByAnna D. Garrett, PharmD, BCPS, CPP

September 1st 2007

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

WORLD HEALTH ORGANIZATION STUDIES TRAVEL RISKS

ByAnna D. Garrett, PharmD, BCPS, CPP

September 1st 2007

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

NEW ORAL ANTICOAGULANTS SHOW PROMISE IN PHASE 3 STUDIES

ByAnna D. Garrett, PharmD, BCPS, CPP

September 1st 2007

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

VTE RISK REDUCED WITH LONGER DURATION OF PROPHYLAXIS

ByAnna D. Garrett, PharmD, BCPS, CPP

September 1st 2007

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

WARFARIN-RELATED COMPLICATIONS INCREASE WITH AGE

ByAnna D. Garrett, PharmD, BCPS, CPP

August 1st 2007

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

IS NATTOKINASE A NATURAL ALTERNATIVE TO WARFARIN?

ByAnna D. Garrett, PharmD, BCPS, CPP

August 1st 2007

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

HIGH RATES OF WARFARIN-RELATED AEs IN NURSING HOMES

ByAnna D. Garrett, PharmD, BCPS, CPP

August 1st 2007

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

LONG-TERM ASPIRIN USE MAY REDUCE RISK OF SOME CANCERS

ByAnna D. Garrett, PharmD, BCPS, CPP

August 1st 2007

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

ACETAMINOPHEN INTERACTION MAY PUT PATIENTS AT RISK

ByAnna D. Garrett, PharmD, BCPS, CPP

July 1st 2007

FDA APPROVES FIRST BIOLOGIC TO TREAT PROTEIN C DEFICIENCY

ByAnna D. Garrett, PharmD, BCPS, CPP

July 1st 2007

LOW-DOSE ASPIRIN BEST FOR PREVENTING CARDIOVASCULAR DISEASE

ByAnna D. Garrett, PharmD, BCPS, CPP

July 1st 2007

OUT-OF-RANGE INRs COMMON AMONG WARFARIN PATIENTS IN ER

ByAnna D. Garrett, PharmD, BCPS, CPP

June 1st 2007

THE DEBATE CONTINUES ON LENGTH OF THERAPY

ByAnna D. Garrett, PharmD, BCPS, CPP

June 1st 2007

METABOLIC SYNDROME MAY CONTRIBUTE TO RISK OF VTE

ByAnna D. Garrett, PharmD, BCPS, CPP

June 1st 2007

WOMEN MAY NOT BENEFIT FROM ASPIRIN THERAPY

ByAnna D. Garrett, PharmD, BCPS, CPP

June 1st 2007

RACE MAY AFFECT FILLING OF WARFARIN PRESCRIPTIONS

ByAnna D. Garrett, PharmD, BCPS, CPP

May 1st 2007

ORAL CORTICOSTEROID THERAPY MAY INCREASE INR

ByAnna D. Garrett, PharmD, BCPS, CPP

May 1st 2007

SMOKING AFFECTS WARFARIN THERAPY

ByAnna D. Garrett, PharmD, BCPS, CPP

May 1st 2007

NEW ORAL ANTICOAGULANTS UNDER STUDY

ByAnna D. Garrett, PharmD, BCPS, CPP

May 1st 2007

ABCD SCORING VALIDATED

ByAnna D. Garrett, PharmD, BCPS, CPP

April 1st 2007

ANTICOAGULANT USE SUBOPTIMAL

ByAnna D. Garrett, PharmD, BCPS, CPP

April 1st 2007

GENETICS 101: COMMON INHERITED CLOTTING DISORDERS

ByAnna D. Garrett, PharmD, BCPS, CPP

April 1st 2007

BEVERAGES MAY BE SOURCE OF INR INSTABILITY

ByAnna D. Garrett, PharmD, BCPS, CPP

April 1st 2007

ADVISORY ISSUED REGARDING ANTIPLATELET THERAPY AFTER STENT PLACEMENT

ByAnna D. Garrett, PharmD, BCPS, CPP

March 1st 2007

Anna D. Garrett, PharmD, BCPS, CPP

Articles by Anna D. Garrett, PharmD, BCPS, CPP

coagulation counseling

coagulation counseling

FOLIC ACID REDUCES RISK OF STROKE

FDA APPROVES UPDATED WARFARIN INFO

FONDAPARINUX MAY BE OPTION FOR HIT

INTERACTION REGISTRY AVAILABLE

META-ANALYSIS REINFORCES VALUE OF WARFARIN AND ANTIPLATELET AGENTS

WORLD HEALTH ORGANIZATION STUDIES TRAVEL RISKS

NEW ORAL ANTICOAGULANTS SHOW PROMISE IN PHASE 3 STUDIES

VTE RISK REDUCED WITH LONGER DURATION OF PROPHYLAXIS

WARFARIN-RELATED COMPLICATIONS INCREASE WITH AGE

IS NATTOKINASE A NATURAL ALTERNATIVE TO WARFARIN?

HIGH RATES OF WARFARIN-RELATED AEs IN NURSING HOMES

LONG-TERM ASPIRIN USE MAY REDUCE RISK OF SOME CANCERS

ACETAMINOPHEN INTERACTION MAY PUT PATIENTS AT RISK

FDA APPROVES FIRST BIOLOGIC TO TREAT PROTEIN C DEFICIENCY

LOW-DOSE ASPIRIN BEST FOR PREVENTING CARDIOVASCULAR DISEASE

OUT-OF-RANGE INRs COMMON AMONG WARFARIN PATIENTS IN ER

THE DEBATE CONTINUES ON LENGTH OF THERAPY

METABOLIC SYNDROME MAY CONTRIBUTE TO RISK OF VTE

WOMEN MAY NOT BENEFIT FROM ASPIRIN THERAPY

RACE MAY AFFECT FILLING OF WARFARIN PRESCRIPTIONS

ORAL CORTICOSTEROID THERAPY MAY INCREASE INR

SMOKING AFFECTS WARFARIN THERAPY

NEW ORAL ANTICOAGULANTS UNDER STUDY

ABCD SCORING VALIDATED

ANTICOAGULANT USE SUBOPTIMAL

GENETICS 101: COMMON INHERITED CLOTTING DISORDERS

BEVERAGES MAY BE SOURCE OF INR INSTABILITY

ADVISORY ISSUED REGARDING ANTIPLATELET THERAPY AFTER STENT PLACEMENT

Trending on Pharmacy Times

Ban Synthetic 7-OH: Natural Leaf Kratom Presents No Major Health Risk

Pharmacists Key to Counseling and Monitoring Patients Transitioning to Low-Sodium Oxybate